证券日报网讯12月11日，英诺特在互动平台回答投资者提问时表示，公司高度重视与资本市场的沟通交 流，未来将通过业绩说明会、路演与反路演、投资者热线、IR邮箱、上证e互动等多种方式加强与资本 市场的沟通交流，建立多元化的投资者沟通机制，积极传递公司价值。 ...

Group 1 - The company confirmed that its current production capacity effectively meets market demand [1] - There are no reported capacity bottlenecks or supply chain challenges at this time [1] - The company expressed gratitude for investor interest and engagement [1]

（文章来源：证券日报） 证券日报网讯 12月8日，英诺特在互动平台回答投资者提问时表示，公司销售情况请关注公司披露的定 期报告或相关公告。 ...

Core Viewpoint - Innotech's stock experienced a decline of 2.24% on December 3, with a trading volume of 67.23 million yuan, indicating a challenging market environment for the company [1]. Group 1: Financial Performance - For the period from January to September 2025, Innotech reported a revenue of 330 million yuan, representing a year-on-year decrease of 36.56% [2]. - The net profit attributable to shareholders for the same period was 131 million yuan, reflecting a year-on-year decline of 46.37% [2]. - Cumulative cash dividends since the company's A-share listing amount to 152 million yuan [3]. Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of Innotech's shareholders increased to 8,037, marking a rise of 10.57% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.86% to 8,627 shares [2]. - On December 3, Innotech's financing balance was 184 million yuan, accounting for 8.11% of its market capitalization, which is below the 10% threshold over the past year, indicating a low financing level [1].

Core Viewpoint - Beijing Innotech Biotechnology Co., Ltd. has recently obtained a new product qualification, enhancing its market expansion capabilities and core competitiveness [2][3]. Group 1: Recent Qualification - The company has acquired one new product qualification, which is intended for in vitro qualitative detection of Helicobacter pylori antigens in human fecal samples. This product is suitable for both professional medical personnel in medical institutions and for consumer self-testing [2]. Group 2: Impact on the Company - The acquisition of this qualification broadens the range of products offered by the company, thereby improving its market expansion capabilities and core competitiveness [3].

证券代码：688253 证券简称：英诺特 公告编号：2025-060 北京英诺特生物技术股份有限公司关于公司近期获 得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称"公司"）近期新取得产品资 质 1 项，具体情况如下表所示： | 北京英诺特生物技术 | 幽门螺杆菌抗原检测试 | 国械注准 | 2025/11/25 | 2030/11/24 | | --- | --- | --- | --- | --- | | 获批主体 股份有限公司 | 产品名称 剂盒（乳胶法） | 注册证号（备案号） 20253402376 | 发证日期 | 有效期至 | 本产品预期用途为用于体外定性检测人粪便样本中幽门螺杆菌抗原，既适用 于专业医务人员在医疗单位进行人粪便样本中的幽门螺杆菌抗原检测，也适用于 消费者自测。 上述资质的取得，拓宽了公司产品的种类，进一步提高了公司的市场拓展能 力及核心竞争力。 三、风险提示 上述产品的实际销售受到市场需求、市场 ...

Core Viewpoint - The company, Innotech (688253.SH), has recently obtained a new product qualification for a Helicobacter pylori antigen detection kit, which enhances its product range and market competitiveness [1] Product Qualification - The newly acquired product is a Helicobacter pylori antigen detection kit (latex method) with registration number 20253402376 [1] - The intended use of this product is for the qualitative detection of Helicobacter pylori antigen in human fecal samples, suitable for both professional medical personnel and consumer self-testing [1] Market Expansion - The acquisition of this qualification broadens the company's product offerings, thereby improving its market expansion capabilities and core competitiveness [1]

Core Viewpoint - InnoTech (688253.SH) has recently obtained a new product qualification for a Helicobacter pylori antigen detection kit, enhancing its product range and market competitiveness [1] Product Qualification - The newly acquired product is a Helicobacter pylori antigen detection kit (latex method) with registration number 20253402376 [1] - The intended use of this product is for the qualitative detection of Helicobacter pylori antigen in human fecal samples, suitable for both professional medical personnel in healthcare settings and for consumer self-testing [1] Market Expansion - The acquisition of this qualification broadens the company's product offerings, thereby improving its market expansion capabilities and core competitiveness [1]

Core Viewpoint - InnoTech (688253) has recently obtained a new product qualification for a Helicobacter pylori antigen test kit (latex method), which is intended for in vitro qualitative detection of Helicobacter pylori antigen in human fecal samples [1] Group 1 - The product is suitable for use by healthcare professionals in medical institutions for detecting Helicobacter pylori antigen in human fecal samples [1] - The test kit is also designed for consumer self-testing [1]

Core Viewpoint - The company has recently obtained a new product qualification for a Helicobacter pylori antigen detection kit (latex method), which enhances its product range and market competitiveness, although the actual sales impact remains uncertain [1] Group 1: Product Qualification - The company has acquired a new product qualification for the Helicobacter pylori antigen detection kit, with registration number 国械注准20253402376 [1] - The certification was issued on November 25, 2025, and is valid until November 24, 2030 [1] - This product is intended for in vitro qualitative detection of Helicobacter pylori antigen in human fecal samples, suitable for both professional medical personnel and consumer self-testing [1] Group 2: Market Impact - The new qualification broadens the company's product offerings, potentially enhancing its market expansion and core competitiveness [1] - However, the actual sales performance of the product is influenced by various factors, making the impact on financial performance difficult to predict [1]